422 related articles for article (PubMed ID: 33257619)
1. The shortcomings of tocilizumab in COVID-19.
Tirupathi R; Bharathidasan K; Areti S; Kaur J; Salim S; Al-Tawfiq JA
Infez Med; 2020 Dec; 28(4):465-468. PubMed ID: 33257619
[TBL] [Abstract][Full Text] [Related]
2. Is IL-6 a key cytokine target for therapy in COVID-19?
Jones SA; Hunter CA
Nat Rev Immunol; 2021 Jun; 21(6):337-339. PubMed ID: 33850327
[TBL] [Abstract][Full Text] [Related]
3. Cytokine Profiles Before and After Immune Modulation in Hospitalized Patients with COVID-19.
Azmy V; Kaman K; Tang D; Zhao H; Dela Cruz C; Topal JE; Malinis M; Price CC
J Clin Immunol; 2021 May; 41(4):738-747. PubMed ID: 33459964
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic Role of Tocilizumab in SARS-CoV-2-Induced Cytokine Storm: Rationale and Current Evidence.
Pelaia C; Calabrese C; Garofalo E; Bruni A; Vatrella A; Pelaia G
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33802761
[TBL] [Abstract][Full Text] [Related]
5. Tocilizumab prescribing criteria for COVID-19 patients.
Al-Qaaneh AM; Al-Ghamdi FH
Hum Vaccin Immunother; 2021 Apr; 17(4):1128. PubMed ID: 33079613
[No Abstract] [Full Text] [Related]
6. Insights from compassionate use of tocilizumab for COVID-19 to inform appropriate design of randomised controlled trials.
Baker EH; Patel K; Ball J; Edwards S; Harrison TS; Kaul A; Koh M; Krishna S; Leaver S; Kumar V; Forton DM
Br J Clin Pharmacol; 2021 Mar; 87(3):1584-1586. PubMed ID: 32656822
[No Abstract] [Full Text] [Related]
7. Antibody response to SARS-CoV-2 in patients receiving glucocorticoids with or without tocilizumab for COVID-19-associated hyperinflammation.
Janssen MTHF; Ramiro S; Landewé RBM; Magro-Checa C; Mostard RLM
Ann Rheum Dis; 2021 Oct; 80(10):1362-1363. PubMed ID: 33958327
[No Abstract] [Full Text] [Related]
8. Use of the interleukin 6 inhibitor tocilizumab in Japanese patients with cytokine release syndrome caused by COVID-19-related acute respiratory distress syndrome: A case series.
Nakamura H; Miyagi K; Otsuki M; Higure Y; Nishiyama N; Kinjo T; Nakamatsu M; Haranaga S; Tateyama M; Fujita J
Respir Investig; 2020 Nov; 58(6):510-512. PubMed ID: 33067149
[No Abstract] [Full Text] [Related]
9. Experience of using tocilizumab for treatment in Indonesian patients with severe COVID-19.
Widysanto A; Kurniawan A; Lugito NPH; Yuniarti M; Gunawan C; Angela ; Wiryanto J; Levinna ; Pradhana TM
Cytokine; 2021 Feb; 138():155393. PubMed ID: 33333393
[TBL] [Abstract][Full Text] [Related]
10. Tocilizumab as a Treatment for 'Cytokine Storm Syndrome' in COVID-19: A Case Report.
Syam AF; Pitoyo CW; Suhendro S; Zulkarnain B; Indrasari ND; Aditianingsih D; Irawan C; Susilo A; Rumende CM; Wijaya IP; Ibrahim F; Rasmin M; Alwi I; Makmun D
Acta Med Indones; 2021 Apr; 53(2):194-201. PubMed ID: 34251348
[TBL] [Abstract][Full Text] [Related]
11. Clinical characteristics and predictors of survival in adults with coronavirus disease 2019 receiving tocilizumab.
Morrison AR; Johnson JM; Griebe KM; Jones MC; Stine JJ; Hencken LN; To L; Bianchini ML; Vahia AT; Swiderek J; Ramesh MS; Peters MA; Smith ZR
J Autoimmun; 2020 Nov; 114():102512. PubMed ID: 32646770
[TBL] [Abstract][Full Text] [Related]
12. Sarilumab (IL-6R antagonist) in critically ill patients with cytokine release syndrome by SARS-CoV2.
Corominas H; Castellví I; Diaz-Torné C; Matas L; de la Rosa D; Mangues MA; Moya P; Pomar V; Benito N; Moga E; Sosa NH; Casademont J; Domingo P
Medicine (Baltimore); 2021 May; 100(19):e25923. PubMed ID: 34106658
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-6 blockade treatment for COVID-19 associated cytokine release syndrome in a patient with poorly controlled chronic myeloid leukaemia.
Ranger A; Haji R; Kaczmarski R; Danga A
Br J Haematol; 2020 Aug; 190(3):e128-e130. PubMed ID: 32480422
[No Abstract] [Full Text] [Related]
14. Repurposed Tocilizumab in Patients with Severe COVID-19.
Tian J; Zhang M; Jin M; Zhang F; Chu Q; Wang X; Chen C; Yue H; Zhang L; Du R; Zhao D; Zeng Z; Zhao Y; Liu K; Wang M; Hu K; Miao X; Zhang H
J Immunol; 2021 Feb; 206(3):599-606. PubMed ID: 33298617
[TBL] [Abstract][Full Text] [Related]
15. Tocilizumab in SARS-CoV-2 Patients with the Syndrome of Cytokine Storm: A Narrative Review.
Kulanthaivel S; Kaliberdenko VB; Balasundaram K; Shterenshis MV; Scarpellini E; Abenavoli L
Rev Recent Clin Trials; 2021; 16(2):138-145. PubMed ID: 32940187
[TBL] [Abstract][Full Text] [Related]
16. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial.
Declercq J; Van Damme KFA; De Leeuw E; Maes B; Bosteels C; Tavernier SJ; De Buyser S; Colman R; Hites M; Verschelden G; Fivez T; Moerman F; Demedts IK; Dauby N; De Schryver N; Govaerts E; Vandecasteele SJ; Van Laethem J; Anguille S; van der Hilst J; Misset B; Slabbynck H; Wittebole X; Liénart F; Legrand C; Buyse M; Stevens D; Bauters F; Seys LJM; Aegerter H; Smole U; Bosteels V; Hoste L; Naesens L; Haerynck F; Vandekerckhove L; Depuydt P; van Braeckel E; Rottey S; Peene I; Van Der Straeten C; Hulstaert F; Lambrecht BN
Lancet Respir Med; 2021 Dec; 9(12):1427-1438. PubMed ID: 34756178
[TBL] [Abstract][Full Text] [Related]
17. Tocilizumab use in patients with moderate to severe COVID-19: A retrospective cohort study.
Chilimuri S; Sun H; Alemam A; Kang KS; Lao P; Mantri N; Schiller L; Sharabun M; Shehi E; Tejada J; Yugay A; Nayudu SK
J Clin Pharm Ther; 2021 Apr; 46(2):440-446. PubMed ID: 33098139
[TBL] [Abstract][Full Text] [Related]
18. Tocilizumab challenge: A series of cytokine storm therapy experiences in hospitalized COVID-19 pneumonia patients.
Borku Uysal B; Ikitimur H; Yavuzer S; Ikitimur B; Uysal H; Islamoglu MS; Ozcan E; Aktepe E; Yavuzer H; Cengiz M
J Med Virol; 2020 Nov; 92(11):2648-2656. PubMed ID: 32484930
[TBL] [Abstract][Full Text] [Related]
19. Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial.
Maes B; Bosteels C; De Leeuw E; Declercq J; Van Damme K; Delporte A; Demeyere B; Vermeersch S; Vuylsteke M; Willaert J; Bollé L; Vanbiervliet Y; Decuypere J; Libeer F; Vandecasteele S; Peene I; Lambrecht B
Trials; 2020 Jun; 21(1):468. PubMed ID: 32493441
[TBL] [Abstract][Full Text] [Related]
20. Audio Interview: Tocilizumab and Covid-19.
Rubin EJ; Baden LR; Morrissey S
N Engl J Med; 2020 Oct; 383(17):e114. PubMed ID: 33085870
[No Abstract] [Full Text] [Related]
[Next] [New Search]
